BAYRY
Get informed when a big investor buys or sells
+ FollowMarch 4, 2026 - AI Summary
Overvalued by 51.9% based on the discounted cash flow analysis.
| Market cap | $48.41 Billion |
|---|---|
| Enterprise Value | $83.95 Billion |
| Dividend Yield | $0.03 (0.25%) |
| Earnings per Share | $-0.88 |
| Beta | 0.83 |
| Outstanding Shares | 3,929,696,328 |
| P/E Ratio | -24.99 |
|---|---|
| PEG | 11.79 |
| Price to Sales | 1.03 |
| Price to Book Ratio | 1.76 |
| Enterprise Value to Revenue | 1.78 |
| Enterprise Value to EBIT | 15.68 |
| Enterprise Value to Net Income | -47 |
| Total Debt to Enterprise | 0.47 |
| Debt to Equity | 1.35 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 0.17%▼ 0.00% |
|---|---|
| Total Invested | $93.52M▲ 18.77% |
| Investors Holding | 15▼ 1.00% |
No data
Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. It operates through the following segments: Pharmaceuticals, Consumer Health, Crop Science, Ani...